

CE Symposia at the 2021 NCODA Fall Summit

OCTOBER 21-22, 2021

THURSDAY, OCTOBER 21, 2021

TIME	SESSION	FACULTY	ROOM
1:15 PM - 2:15 PM	Locally Advanced and Metastatic Bladder Cancer: Transformation of the Treatment Paradigm	Kirollos S. Hanna, PharmD, BCPS, BCOP	Paradise 5-8
2:15 PM - 3:15 PM	Evolving Treatment Strategies for Adjuvant and Metastatic Melanoma: A Multidisciplinary Approach to Care	Megan May, PharmD, BCOP	Paradise 5-8
3:30 PM - 4:30 PM	Oncology Biosimilars: Educating the Oncology Health Care Team to Facilitate Implementation into Clinical Practice	Megan May, PharmD, BCOP	Paradise 5-8
5:20 PM - 6:20 PM	New and Emerging Oral Oncolytics and the Role of the Oncology Team in Optimizing Patient Outcomes	Ashley E. Glode, PharmD, BCOP	Arizona Ballroom

FRIDAY, OCTOBER 22, 2021

TIME	SESSION	FACULTY	ROOM
10:00 AM - 11:00 AM	Exploring the Advancements of Evidence-Based Testing and Treatment Strategies in CLL	Anthony J. Perissinotti, PharmD, BCOP	Paradise 5-8
10:00 AM - 11:00 AM	NCODA: Exploring Strategies for Treating Solid Tumors With PARP Inhibitors	Jason Bergsbaken, PharmD, MBA, BCOP	Arizona Ballroom

TARGET AUDIENCE

These continuing education programs are directed toward pharmacists, pharmacy technicians, physicians, and nurses involved in the treatment of patients with cancer, including those in clinical and operational roles in a variety of practice settings.

HOW TO RECEIVE CREDIT

After attending the CE sessions held during the 2021 NCODA Fall Summit and completing the online evaluation forms, attendees may request credit for the activities in which they participated by following the directions below. **All attendees must request their credit by December 21, 2021.**

OBTAINING CREDIT INSTRUCTIONS FOR PHARMACISTS AND PHARMACY TECHNICIANS

- Go to: www.pharmacytimes.org/NCODA2021 to find a list of evaluations for each session.
- For pharmacy technicians, go to: www.pharmacytimes.org/NCODA2021-techs
- A PTCE account is required to access the evaluations.
- If you do not have an account, create one here: www.pharmacytimes.org/register
- Select and complete the evaluation for the session you viewed.

Your credit will be uploaded to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net.


NOTE: Participation data will not be uploaded into CPE Monitor if you do not have your NABP (e-profile ID) number and date of birth entered. If you do not have an NABP number in your profile, you will only receive a certificate of participation. If you have any questions concerning this conference, please call us at 800-597-6372 or email us at CEinfo@pharmacytimes.com.

If you participated in more than 1 session, you may return to the initial link for additional evaluations.

OBTAINING CREDIT INSTRUCTIONS FOR PHYSICIANS AND NURSES

- Go to www.gotoper.com/go/ncoda21-eval to find a list of evaluations for each session.
 - A Physicians Education Resource® account is required to access the evaluations.
 - If you do not have an account, create one here: www.education.gotoper.com/register
- Select and complete the evaluation for the session you viewed and click “Next.”
- If you participated in more than 1 session, you may return to take additional evaluations after submitting the form.
- After submitting an evaluation for credit, click the link “Click here to take other evaluations” to return to the list of sessions.

ACCREDITATION/DESIGNATION OF CREDIT

 Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Each activity is approved for a maximum of 1.0 contact hour (0.10 CEU) under the ACPE universal activity numbers (UAN) which will be provided at the conclusion of each session.

Pharmacists, pharmacy technicians, physicians, and nurses should claim only the credit commensurate with the extent of their participation in the activities.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource®, LLC and Pharmacy Times Continuing Education™. Physicians' Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 contact hour.

SESSION	UAN
Locally Advanced and Metastatic Bladder Cancer: Transformation of the Treatment Paradigm	0290-0000-21-352-L01-P 0290-0000-21-353-L01-T
Evolving Treatment Strategies for Adjuvant and Metastatic Melanoma: A Multidisciplinary Approach to Care	0290-0000-21-354-L01-P 0290-0000-21-355-L01-T
Oncology Biosimilars: Educating the Oncology Health Care Team to Facilitate Implementation into Clinical Practice	0290-0000-21-348-L01-P 0290-0000-21-349-L01-T
New and Emerging Oral Oncolytics and the Role of the Oncology Team in Optimizing Patient Outcomes	0290-0000-21-350-L01-P 0290-0000-21-351-L01-T
Exploring the Advancements of Evidence-Based Testing and Treatment Strategies in CLL	0290-0000-21-356-L01-P 0290-0000-21-357-L01-T
Exploring Strategies for Treating Solid Tumors With PARP Inhibitors	0290-0000-21-358-L01-P 0290-0000-21-359-L01-T

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

These CE symposia are supported by MJH Life Sciences, the parent company of *Pharmacy Times*® and *PTCE*.

DISCLOSURE POLICY AND RESOLUTION OF CONFLICTS OF INTEREST (COIs)

As a sponsor accredited by the ACPE, it is the policy of *PTCE* to ensure fair balance, independence, objectivity, and scientific rigor in all of its CPE activities. In compliance with ACPE guidelines, *PTCE* requires everyone who is in a position to control the content of a CPE activity to disclose all relevant financial relationships with commercial interests. The ACPE defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, *PTCE* is required by the ACPE to resolve all COIs. *PTCE* has identified and resolved all COIs prior to the start of this activity by using a multistep process.

FACULTY, STAFF, AND PLANNERS' DISCLOSURES

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Ashley E. Glode, PharmD, BCOP
Megan May, PharmD, BCOP

Anthony J. Perissinotti, PharmD, BCOP
Jason Bergsbaken, PharmD, MBA, BCOP

Pharmacy Times Continuing Education™ Planning Staff

Jim Palatine, RPh, MBA
Amy Seung, PharmD, BCOP, FHOPA
Kelly McCormick

Susan Pordon
Brianna Winters
Chloe Taccetta

LOCATION
Paradise
5-8

The following individual has relevant financial relationships with commercial interests to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers Bureau	Shareholder	Other
Kirollos S. Hanna, PharmD, BCPS, BCOP		AbbVie, SeaGen	AbbVie, Astellas, BeiGene, Bristol Myers Squibb, Exelixis, SeaGen		

*Information accurate at time of posting.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

OFF-LABEL DISCLOSURE AND DISCLAIMER

Continuing professional education (CPE) activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.


The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of *Pharmacy Times* Continuing Education™ or the companies that provided commercial support for this activity.

If you have any questions concerning this broadcast, please call us at 800-597-6372 or email us at CEinfo@pharmacytimes.com.

Locally Advanced and Metastatic Bladder Cancer: Transformation of the Treatment Paradigm

Thursday, October 21, 2021 • 1:15 PM – 2:15 PM

FACULTY



Kirollos S. Hanna, PharmD, BCPS, BCOP

Oncology Pharmacy Manager
M Health Fairview
Maple Grove, MN
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, MN

PROGRAM DESCRIPTION

In patients with bladder cancer, the use of biomarkers to predict response to therapy and assess prognosis is growing. In patients who are unable to tolerate platinum agents or whose tumors express PD-L1, immune checkpoint inhibitors have a significant role. To prevent disease recurrence and progression, timely recognition and appropriate management is imperative, and practitioners on the oncology care team must stay ahead of advancements in biomarker testing, maintenance therapy options, and expanded indications to determine targeted approaches to treatment. Evidence supporting use of immunotherapeutic and targeted therapies in patients will be presented to assist members of the oncology care team in making proactive treatment decisions and individualized management plans for patients with bladder cancer in accordance with guideline recommendations.

EDUCATIONAL OBJECTIVES

At the completion of this activity, pharmacists, physicians, and nurses will be able to:

- Characterize potential biomarkers to optimize the selection of patients with bladder cancer eligible for immune checkpoint inhibitors and targeted agents
- Explain the benefits and limitations of current guideline-based treatments for bladder cancer and the appropriate use of novel and emerging agents
- Apply recent and emerging data to tailor treatment regimens for patients with bladder cancer

At the completion of this activity, pharmacy technicians will be able to:

- Articulate the rationale for use of biomarkers in selection of therapy for patients with bladder cancer
- Discuss the benefits and limitations of current guideline-based treatments for bladder cancer
- Recall place in therapy of new and emerging agents for patients with bladder cancer

Evolving Treatment Strategies for Adjuvant and Metastatic Melanoma:

A Multidisciplinary Approach to Care

Thursday, October 21, 2021 • 2:15 PM – 3:15 PM

FACULTY



Megan May, PharmD, BCOP

Ambulatory Oncology Clinical Pharmacy Specialist
Baptist Health System
Lexington, KY

PROGRAM DESCRIPTION

Use of immune checkpoint inhibitors and targeted BRAF/MEK combination therapy have expanded treatment options and improved outcomes for patients with adjuvant and metastatic melanoma. Members of the oncology health care team must be familiar with biomarkers to guide treatment selection and therapy sequencing, as these emerging and investigational regimens have the potential to increase recurrence-free survival rates in patients with melanoma. However, with multiple agents and routes of administration used in a single regimen, treatment for adjuvant and metastatic melanoma can be complex. Monitoring for therapy tolerance and specific adverse effects of melanoma treatment regimens requires coordination of care among the multidisciplinary oncology care team. Considerations for effective patient counseling and management throughout the continuum of treatment will be discussed.

EDUCATIONAL OBJECTIVES

At the completion of this activity, pharmacists, physicians, and nurses will be able to:

- Compare data that support approved and emerging therapy options in adjuvant and metastatic melanoma
- Employ best practices of a multidisciplinary team to address adverse effects and treatment adherence in patients with melanoma
- At the completion of this activity, pharmacy technicians will be able to:
- Discuss data that support approved and emerging therapy options in adjuvant and metastatic melanoma
- Give examples of best practices to address adverse effects and treatment adherence in patients with melanoma

At the completion of this activity, pharmacy technicians will be able to:

- Discuss data that support approved and emerging therapy options in adjuvant and metastatic melanoma
- Give examples of best practices to address adverse effects and treatment adherence in patients with melanoma

Oncology Biosimilars:

Educating the Oncology Health Care Team to Facilitate Implementation into Clinical Practice

Thursday, October 21, 2021 • 3:30 PM – 4:30 PM

FACULTY



Megan May, PharmD, BCOP

Ambulatory Oncology Clinical Pharmacy Specialist
Baptist Health System
Lexington, KY

PROGRAM DESCRIPTION

The number of biosimilars available for oncology-related indications continues to increase. Despite the growing availability of oncology biosimilar products in clinical practice, clinicians may be reluctant to modify prescribing practices or formularies because of the complex manufacturing and development process of these agents. Oncology care practitioners are often involved with providing education about risks and benefits of oncology biosimilars and their use for either supportive care or treatment. Additionally, clinical practice guidelines that have been recently updated to promote safe use and appropriate substitution of biosimilars for managing patients will be reviewed. This activity will address barriers to adoption of biosimilars members of the oncology care team may encounter in their practice and present strategies to promote the safe use of biosimilars in clinical practice.

EDUCATIONAL OBJECTIVES

At the completion of this activity, pharmacists, physicians, and nurses will be able to:

- Compare the indications for FDA-approved reference biologics and biosimilars that are currently available, as well as those that may reach the market soon
- Identify challenges that may influence implementation of oncology biosimilars in clinical practice
- Apply knowledge of the challenges associated with the adoption of biosimilars into clinical practice to educate patients and members of the oncology health care team

At the completion of this activity, pharmacy technicians will be able to:

- Associate FDA-approved reference biologics with their biosimilars that are currently available, as well as those that may reach the market soon
- Outline challenges that may affect adoption of oncology biosimilars in clinical practice
- Detail how pharmacy technicians can assist with education about biosimilars to patients and members of the oncology health care team

New and Emerging Oral Oncolytics and the Role of the Oncology Team in Optimizing Patient Outcomes

Thursday, October 21, 2021 • 5:20 PM – 6:20 PM

FACULTY



Ashley E. Glode, PharmD, BCOP

Associate Professor
Clinical Pharmacy Specialist
University of Colorado Skaggs School of Pharmacy
University of Colorado Cancer Center
Aurora, CO

PROGRAM DESCRIPTION

Despite challenges related to the COVID-19 pandemic throughout 2020, numerous oral oncolytics received FDA approval, and many more are under investigation with expected approvals. The oncology care team needs to stay ahead and be prepared for these important developments. Novel oral oncolytics have the potential to impact patient care for both solid and hematologic malignancies throughout the patient journey. This activity will review drug pharmacology, mechanism of action, medication dosing, and management considerations for recently approved and pipeline agents. By determining the appropriate place in therapy for oral oncolytic agents, physicians, nurses, and pharmacists can guide treatment decisions and assist in developing patient-specific management plans to optimize care for patients on these therapies.

EDUCATIONAL OBJECTIVES

At the completion of this activity, pharmacists, physicians, and nurses will be able to:

- Compare the pharmacology, mechanisms of action, and safety data for newly approved and emerging anticancer therapies
- Analyze the latest data on efficacy for newly approved and pipeline anticancer therapies
- Examine the roles of members of the oncology multidisciplinary team in the support and management of patients receiving treatment with recently approved anticancer therapies

At the completion of this activity, pharmacy technicians will be able to:

- Describe the mechanisms of action for newly approved and emerging anticancer therapies
- Recall indications for newly approved and pipeline anticancer therapies
- Detail opportunities for pharmacy technicians to assist the oncology multidisciplinary team in the support and management of patients receiving treatment with recently approved anticancer therapies

Exploring the Advancements of Evidence-Based Testing and Treatment Strategies in CLL

Friday, October 22, 2021 • 10:00 AM – 11:00 AM

FACULTY



Anthony J. Perissinotti, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan
Ann Arbor, MI

PROGRAM DESCRIPTION

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and has a highly variable clinical course. Members of the oncology care team need be aware of prognostic factors influencing treatment decisions. Regimens include multiple single-agent small-molecule inhibitors, but the use of anti-CD20 monoclonal antibodies and oral oncolytics in combination is rapidly progressing the current treatment paradigm. Oncology pharmacists, physicians, and nurses are well positioned to manage patients and educate other health care professionals about adverse effects of immunotherapeutic options. Further consideration will be given to how members of the oncology care team can facilitate access to current and emerging agents and alleviate the economic burden associated with treatment for patients. This program will prepare physicians, nurses, and pharmacists involved in the care of patients with CLL to recommend appropriate therapies for patients and navigate the changing landscape of CLL treatment.

EDUCATIONAL OBJECTIVES

At the completion of this activity, pharmacists, physicians, and nurses will be able to:

- Explain how prognostic testing may vary for patients with chronic lymphocytic leukemia (CLL) based on gene mutation, cytogenetic abnormalities, and minimal residual disease test results
- Interpret recent and emerging data to select treatment strategies appropriate for patients with CLL
- Identify opportunities to improve financial toxicity in patients with CLL

At the completion of this activity, pharmacy technicians will be able to:

- Recognize effects of prognostic testing for patients with chronic lymphocytic leukemia (CLL) based on gene mutation, cytogenetic abnormalities, and minimal residual disease test results
- Review recent and emerging data for treatment strategies in patients with CLL
- Describe the impact of financial toxicity on patients with CLL

Exploring Strategies for Treating Solid Tumors With PARP Inhibitors

Friday, October 22, 2021 • 10:00 AM – 11:00 AM

FACULTY



Jason Bergsbaken, PharmD, MBA, BCOP

Pharmacy Coordinator, Regional Oncology Services
Clinical Assistant Professor
UW Health
University of Wisconsin-Madison School of Pharmacy
Madison, WI

PROGRAM DESCRIPTION

PARP inhibitors have become a focus of clinical investigation, with approved indications across a variety of solid tumors. Predictive biomarkers and diagnostics have increased clinicians' ability to assess individuals who may most likely benefit from use of PARP inhibitors, especially those whose tumors present with BRCA1/2 mutations, as well as identify potential for cancers to become resistant to PARP inhibition therapy. However, the emerging and expanding PARP inhibitors are markedly different from traditional oncology agents. Oncology care professionals need to understand the distinct adverse effect profiles associated with PARP inhibitors in order to safely and effectively integrate them in clinical practice. As the role of PARP inhibitors continues to expand with more personalized treatment regimens and longer periods of treatment, pharmacists, nurses, and physicians must be familiar with available resources that can assist in mitigating financial toxicity and out-of-pocket expenses for patients. This activity will explore strategies for oncology practitioners to employ a multidisciplinary approach to facilitate incorporation of PARP inhibitors in their patient care.

EDUCATIONAL OBJECTIVES

At the completion of this activity, pharmacists, physicians, and nurses will be able to:

- Use the necessary diagnostic testing strategies to determine whether PARP inhibitors will be appropriate treatment options
- Identify PARP inhibitor strategies that align with ovarian, breast, prostate, and pancreatic cancers, based on tumor characteristics
- Determine patient support opportunities for appropriate candidates who are treated with PARP inhibitors

At the completion of this activity, pharmacy technicians will be able to:

- Recall necessary diagnostic testing strategies for treatment with PARP inhibitors
- Indicate PARP inhibitor strategies that align with ovarian, breast, prostate, and pancreatic cancers
- Recognize opportunities and resources available to support patients treated with PARP inhibitors



Jason Bergsbaken, PharmD, MBA, BCOP

Pharmacy Coordinator, Regional Oncology Services
Clinical Assistant Professor
UW Health
University of Wisconsin-Madison School of Pharmacy
Madison, WI

Jason Bergsbaken, PharmD, MBA, BCOP, currently serves as Pharmacy Coordinator, Regional Oncology Services, UW Health and Clinical Assistant Professor, University of Wisconsin-Madison School of Pharmacy in Madison, WI. His responsibilities include the coordination and standardization of pharmaceutical care among UW Carbone Cancer Center partners. Dr Bergsbaken received his Doctor of Pharmacy degree from the University of Wisconsin-Madison. Following graduation, he completed a PGY1 Pharmacy Practice Residency and PGY2 Oncology Pharmacy Residency at UW Health. In his current role, Dr Bergsbaken serves as Secretary of Chemotherapy Review Council which oversees review and approval of chemotherapy regimens for the treatment of adult malignancy at UW Health. Additionally, he has led the implementation of multiple practice advancement initiatives, including pharmacist-led oral chemotherapy management at UW Health. Dr Bergsbaken completed a Master of Business Administration degree through University of Wisconsin-Whitewater.



Ashley E. Glode, PharmD, BCOP

Associate Professor
Clinical Pharmacy Specialist
University of Colorado Skaggs School of Pharmacy
University of Colorado Cancer Center
Aurora, CO

Ashley E. Glode, PharmD, BCOP, is an Assistant Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr Glode received her PharmD degree from Duquesne University and completed her PGY1 pharmacy practice and PGY2 oncology residencies at Yale-New Haven Hospital and Roswell Park Cancer Institute, respectively. Before joining the University of Colorado, Dr Glode was the Clinical Pharmacy Specialist in Hematology and Stem Cell Transplantation and PGY2 Oncology Residency Program Director at the Medical University of South Carolina. In Colorado, her clinical appointment is in the Phase 1/ GI/ head and neck/sarcoma multidisciplinary clinic at the University of Colorado Cancer Center. In 2019 she received HOPA's Patient Advocacy Award and was named one of the Top 40 Under 40 Rising Stars and Emerging Leaders in oncology. She has given numerous presentations on the local and national level and has published many research and review papers in the field of oncology. Her clinical practice and areas of research interest focus on identifying improvements to supportive care interventions and enhancing the quality of life of patients undergoing cancer treatment.



Kirollos S. Hanna, PharmD, BCPS, BCOP

Oncology Pharmacy Manager
 M Health Fairview
 Maple Grove, MN
 Assistant Professor of Pharmacy
 Mayo Clinic College of Medicine
 Rochester, MN

Kirollos S. Hanna, PharmD, BCPS, BCOP, is board certified by the Board of Pharmacy Specialties in oncology pharmacy and pharmacotherapy. He received his doctorate of pharmacy degree from Florida A&M University, completed his general residency at St. Thomas Hospital, Nashville, Tennessee, and his oncology residency at St. Luke's Mountain States Tumor Institute, Boise, Idaho. He is currently an assistant professor of pharmacy at the Mayo Clinic College of Medicine and the oncology pharmacy manager at M Health Fairview, Maple Grove. Dr Hanna's research interests are focused on outcome measures for patients with rare diseases, B-cell malignancies, and genitourinary cancers. He has published over a dozen peer-reviewed manuscripts in various journals including Pharmacotherapy, AJHP, JOPP, AJMC, and JHOP. He is also an active member of the Patient-Centered Outcomes Research Institute, Aplastic Anemia and MDS International Foundation, and the American College of Clinical Pharmacy.



Megan May, PharmD, BCOP

Ambulatory Oncology Clinical Pharmacy Specialist
 Baptist Health System
 Lexington, KY

Megan May, PharmD, BCOP, is a Clinical Oncology Pharmacy Specialist at Baptist Health Lexington's Cancer Center in Lexington, Kentucky. She received her Doctor of Pharmacy from Samford University's McWhorter School of Pharmacy in Birmingham, Alabama and completed a Pharmacy Practice Residency at Shands Jacksonville Medical Center and a Hematology/Oncology Pharmacy Residency at the Medical University of South Carolina. She is a Board-Certified Oncology Pharmacist. In addition to direct patient care, Dr May plays an active role in the education of pharmacy students and residents. She is on multiple committees at Baptist Health Lexington, including Cancer Committee and the Institutional Review Board. In addition, she has authored review articles, presented research posters, and given presentations both regionally and nationally.



Anthony J. Perissinotti, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
 University of Michigan
 Ann Arbor, MI

Anthony J. Perissinotti, PharmD, BCOP, is a Hematology Clinical Pharmacist Specialist at the University of Michigan-Michigan Medicine, clinical team leader of hematology/oncology, and adjunct clinical assistant professor at the University of Michigan College of Pharmacy in Ann Arbor, Michigan. Dr Perissinotti obtained his Doctor of Pharmacy degree from Wayne State University in Detroit, Michigan. He completed his first year of postgraduate residency at the Detroit Medical Center - Harper University Hospital in Detroit, and he completed his second year of postgraduate residency training at The University of Texas MD Anderson Cancer Center in Houston. Dr Perissinotti is a board-certified hematology/oncology pharmacist.

UPCOMING PTCE CONFERENCES		
Directions in Oncology Pharmacy® - Midwest	Virtual Conference	October 23, 2021
Directions in Oncology Pharmacy® - Northeast	Virtual Conference	November 6, 2021
American Society of Health-System Pharmacists Midyear 2021 Clinical Meeting & Exhibition	8 Virtual CE Symposia	December 6-9, 2021



Ensure your pharmacy learning is headed
in the right **direction!**

Earn 6.0 Live CE Credits via Live Broadcast

Midwest Session - Saturday, October 23, 2021

Northeast Session - Saturday, November 6, 2021